Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.930 -0.050 (-2.53%)
Streaming Delayed Price Updated: 12:38 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gain Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Event to be held October 14th at 4 p.m. EST 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected Mid-2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
First Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected in Q2 2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
Via Get News
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
Via ACCESS Newswire
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
Interim Analysis Expected End of 2Q 2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics To Participate in Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics To Present At Biotech Showcase 2025
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform 
From Gain Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.